CN115851924A - Kit for detecting BCR-ABL fusion gene and application thereof - Google Patents
Kit for detecting BCR-ABL fusion gene and application thereof Download PDFInfo
- Publication number
- CN115851924A CN115851924A CN202210873620.0A CN202210873620A CN115851924A CN 115851924 A CN115851924 A CN 115851924A CN 202210873620 A CN202210873620 A CN 202210873620A CN 115851924 A CN115851924 A CN 115851924A
- Authority
- CN
- China
- Prior art keywords
- bcr
- abl1
- kit
- abl
- reaction solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention relates to the technical field of chronic myelocytic leukemia detection, in particular to a kit for detecting BCR-ABL fusion genes and application thereof. The kit comprises: BCR-ABL PCR reaction liquid, reference gene PCR reaction liquid, mixed enzyme liquid, reference substance liquid and reference substance liquid. The mixing ratio of the BCR-ABL PCR reaction liquid to the reference gene PCR reaction liquid to the mixed enzyme liquid is 3 to 4:3 to 4:1. the kit can be matched with a real-time fluorescent PCR technology to quantitatively detect p190/p210/p230 in RNA extracted from a peripheral blood or bone marrow blood sample, has the characteristics of accurate detection result, high sensitivity and good stability, and can provide important basis for diagnosis, curative effect monitoring, tiny residue detection and prognosis of malignant tumors.
Description
Technical Field
The invention relates to the technical field of chronic myelocytic leukemia detection, in particular to a kit for detecting BCR-ABL fusion genes and application thereof.
Background
The information disclosed in this background of the invention is only for enhancement of understanding of the general background of the invention and is not necessarily to be taken as an acknowledgement or any form of suggestion that this information forms the prior art already known to a person skilled in the art.
Chronic Myelogenous Leukemia (CML) is a hematological malignant proliferative disease that occurs in hematopoietic stem cells and is characterized by the production of large amounts of immature leukocytes which accumulate in the bone marrow and inhibit normal hematopoiesis of the bone marrow; and can diffuse through blood throughout the body, resulting in anemia, easy bleeding, infection, organ infiltration, etc. in patients. t (9. More than 90% of CML and 5% -20% of Acute Lymphoblastic Leukemia (ALL) have BCR-ABL fusion genes, but are rarely seen in AML and other hematological diseases. The protein encoded by the BCR-ABL fusion gene has tyrosine kinase activity, resulting in malignant cell proliferation. The position of the BCR-ABL breakpoint can affect the phenotype of the disease, with CML patients expressing predominantly p210, ph-positive ALL expressing predominantly p190, and with p 210-positive patients often expressing a small number of p190 transcripts as well. The detection on the molecular biology level plays an important role in the diagnosis, curative effect monitoring, tiny residue detection and prognosis of malignant tumors. However, the conventional kit for detecting the BCR-ABL fusion gene on the market has the problems of low sensitivity and poor stability.
Disclosure of Invention
The invention aims to realize the detection of p190, p210 and p230 in RNA extracted from peripheral blood or bone marrow blood samples so as to conveniently diagnose malignant tumors on a molecular biology level, and therefore, the invention provides a kit for detecting BCR-ABL fusion genes and application thereof, wherein the kit can be matched with a real-time fluorescence PCR technology to quantitatively detect the p190/p210/p230 in the RNA extracted from the peripheral blood or bone marrow blood samples, and has high sensitivity and good stability. In order to achieve the purpose, the invention discloses the following technical scheme:
in the first aspect of the invention, a kit for detecting a BCR-ABL fusion gene is disclosed, which comprises a BCR-ABL PCR reaction solution, an internal reference gene PCR reaction solution, a mixed enzyme solution, a reference solution and a reference solution.
Further, the mixing ratio of the BCR-ABL PCR reaction solution, the reference gene PCR reaction solution and the mixed enzyme solution is 3-4: 3 to 4:1, preferably 4:4:1.
further, the BCR-ABL PCR reaction solution comprises a BCR-ABL1 p190 reaction solution, a BCR-ABL1 p210 reaction solution and a BCR-ABL1 p230 reaction solution.
Further, the BCR-ABL1 p190 reaction solution comprises the following components in percentage by volume: 12.5. Mu.L of script II U + OneStp qRT-PCR Probe Kit, 1.25. Mu.L of script II U + Enzyme Mixt, 0.06. Mu.L of Triton 100, 0.04. Mu.L of isopropanol, 0.4. Mu.L of ROX internal reference, 0.6. Mu.L of BCR-ABL1 p190 upstream primer, 0.6. Mu.L of BCR-ABL1 p190 downstream primer, and 0.4. Mu.L of BCR-ABL1 Probe; wherein the sequence of the BCR-ABL1 p190 type upstream primer is a nucleotide sequence shown in SED ID NO. 1; the sequence of the BCR-ABL1 p190 type downstream primer is a nucleotide sequence shown in SED ID NO. 2; the sequence of the ABL1 probe is a nucleotide sequence shown in SED ID NO. 9.
Further, the BCR-ABL1 p210 reaction solution comprises the following components in percentage by volume: 12.5 μ L of script II U + OneStep qRT-PCR Probe Kit, 1.25 μ L of script II U + Enzyme Mixt, 0.06 μ L of Triton 100, 0.04 μ L of isopropanol, 0.4 μ L of ROX internal reference, 0.6 μ L of BCR-ABL1 p210 upstream primer, 0.6 μ L of BCR-ABL1 p210 downstream primer, 0.4 μ L of BCR-ABL1 Probe; wherein the sequence of the BCR-ABL1 p210 upstream primer is a nucleotide sequence shown in SED ID NO. 3; the sequence of the BCR-ABL1 p210 downstream primer is a nucleotide sequence shown in SED ID NO. 4.
Further, the BCR-ABL1 p230 reaction solution comprises the following components in percentage by volume: 12.5. Mu.L of script II U + OneStp qRT-PCR Probe Kit, 1.25. Mu.L of script II U + Enzyme Mixt, 0.06. Mu.L of Triton 100, 0.04. Mu.L of isopropanol, 0.4. Mu.L of ROX internal reference, 0.6. Mu.L of BCR-ABL1 p230 upstream primer, 0.6. Mu.L of BCR-ABL1 p230 downstream primer, 0.4. Mu.L of BCR-ABL1 Probe; wherein the sequence of the BCR-ABL1 p230 upstream primer is a nucleotide sequence shown in SED ID NO. 5; the sequence of the BCR-ABL1 p230 downstream primer is a nucleotide sequence shown in SED ID NO. 6.
Further, the reference liquid comprises the following components in percentage by volume: 12.5. Mu.L of script II U + OneStep qRT-PCR Probe Kit, 1.25. Mu.L of script II U + Enzyme Mixt, 0.4. Mu.L of ROX reference, 0.6. Mu.L of ABL1 upstream primer, 0.6. Mu.L of ABL1 downstream primer and 0.4. Mu.L of ABL1 Probe; wherein the sequence of the ABL1 upstream primer is a nucleotide sequence shown in SED ID NO. 7; the sequence of the ABL1 downstream primer is a nucleotide sequence shown in SED ID NO. 8.
Further, the reference liquid comprises the following components in percentage by volume: 12.5. Mu.L of script II U + OneStep qRT-PCR Probe Kit, 1.25. Mu.L of script II U + Enzyme Mixt, 0.4. Mu.L of ROX internal reference, 0.6. Mu.L of BCR-ABL1 p210 upstream primer, 0.6. Mu.L of ABL1 downstream primer, and 0.4. Mu.L of ABL1 Probe.
Further, the mixed enzyme solution includes nuclease-free water and the like.
In the second aspect of the invention, the application of the kit for detecting the BCR-ABL fusion gene in the fields of biology, medicine and the like is disclosed.
Compared with the prior art, the invention has the following beneficial effects: the kit can be matched with a real-time fluorescent PCR technology to quantitatively detect p190/p210/p230 in RNA extracted from a peripheral blood or bone marrow blood sample, has the characteristics of accurate detection result, high sensitivity (the lowest detection limit is 100 copies) and good stability, and can provide important basis for diagnosis, curative effect monitoring, tiny residue detection and prognosis of malignant tumors.
Detailed Description
In the following description, further specific details of the invention are set forth in order to provide a thorough understanding of the invention. The terminology used in the description of the invention herein is for the purpose of describing particular advantages and features of the invention only and is not intended to be limiting of the invention.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Unless otherwise indicated, the drugs or agents used in the present invention are used according to the product instructions or by the conventional methods in the art.
As described above, it is important to realize the detection of p190, p210 and p230 in RNA extracted from peripheral blood or bone marrow blood samples at the molecular biological level for the diagnosis of malignant tumors. Therefore, the invention provides a kit for detecting BCR-ABL fusion genes, and the kit is further explained according to the specific embodiment of the specification.
The sequence of the BCR-ABL1 p190 type upstream primer in the following examples is a nucleotide sequence shown in SED ID NO. 1; the sequence of the BCR-ABL1 p190 type downstream primer is a nucleotide sequence shown in SED ID NO. 2; wherein the sequence of the BCR-ABL1 p210 upstream primer is a nucleotide sequence shown in SED ID NO. 3; the sequence of the BCR-ABL1 p210 downstream primer is a nucleotide sequence shown in SED ID NO. 4; wherein the sequence of the upstream primer of the BCR-ABL1 p230 is a nucleotide sequence shown in SED ID NO. 5; the sequence of the BCR-ABL1 p230 downstream primer is a nucleotide sequence shown by SED ID NO. 6; the sequence of the ABL1 upstream primer is a nucleotide sequence shown by SED ID NO. 7; the sequence of the ABL1 downstream primer is a nucleotide sequence shown in SED ID NO. 8; the sequence of the ABL1 probe is a nucleotide sequence shown in SED ID NO. 9; the upstream primer sequence of the reference gene is a nucleotide sequence shown by SEQ ID NO. 10, the downstream primer is a nucleotide sequence shown by SEQ ID NO. 11, and the probe is a nucleotide sequence shown by SEQ ID NO. 12; see table 1 specifically:
TABLE 1
Example 1
A method for detecting BCR-ABL fusion gene by using a kit comprises the following steps: the method comprises the following steps:
1. type of sample: the received sample type includes EDTA anticoagulated peripheral blood/bone marrow sample.
2. Sample acquisition: the first-time patient takes the sample before treatment; for patients with normal peripheral blood white cell count, 2-4 ml bone marrow or 5-8 ml peripheral blood is extracted, and if the white cell count is increased or decreased, the sample collection amount is adjusted accordingly (the total number of nucleated cells is 5 × 10) 6 Above).
3. Container and additive type: EDTA anticoagulation tube.
4. The required instrumentation: ABI7500 fluorescent PCR detector.
5. Environmental and security control: the temperature is 18-25 ℃, the humidity is 10-75%, and all workers must wear gloves and work clothes during the operation. The gloves must be removed before leaving the laboratory and entering the office. The waste generated in the using process is treated according to relevant regulations. The workbench is cleaned by 3000mg/L sodium hypochlorite solution after the work is finished, and the space is irradiated by ultraviolet rays for 1h.
6. The components of the detection kit are shown in tables 2 to 7:
TABLE 2 BCR-ABL1 p190 reaction solution
TABLE 3BCR-ABL1 p210 reaction solution
TABLE 4 BCR-ABL1 p230 reaction solution
TABLE 5 control solutions (ABL 1 reagent)
TABLE 6 reference (BCR-ABL 1 reagent)
TABLE 7 preparation of reference gene PCR reaction solution
The PCR reaction solution for detecting the reference gene comprises an upstream primer shown by SEQ ID NO. 10, a downstream primer shown by SEQ ID NO. 11 and a probe shown by SEQ ID NO. 12. The components in the kit are stored in the temperature environment of-20 to-15 ℃ and are melted at room temperature in advance before use.
7. RNA extraction: the method can be obtained by referring to the existing RNA extraction method.
8. And (3) detection process:
(1) Preparation of reagents: and taking out the BCR-ABL PCR reaction solution, the reference gene PCR reaction solution, the mixed enzyme solution, the reference substance solution and the reference substance solution from the amplification kit, melting at room temperature, respectively oscillating and uniformly mixing the reagents, and centrifuging at the rotating speed of 2000rpm for 10s for later use.
(2) The reaction system is prepared as follows: sucking 12 mu L of BCR-ABL1 p190 reaction liquid, 12 mu L of BCR-ABL1 p210 reaction liquid, 12 mu L of BCR-ABL1 p230 reaction liquid, 36 mu L of reference gene PCR reaction liquid and 9 mu L of mixed enzyme liquid (nuclease-free water), and uniformly mixing the 5 reagents to obtain the PCR premixed solution. 3 PCR tubes were taken and 10. Mu.L of the premix was added to each tube.
(3) Sample adding: mu.L of the above-mentioned control solution, reference solution and sample (peripheral blood) were sampled, and the samples were added to the three PCR tubes containing the PCR premix in step (2), and the caps were closed and transferred to the detection zone.
(4) And (3) PCR amplification:
(i) The amplification conditions were: placing the three PCR tubes obtained in the step (3) in an ABI7500 fluorescent PCR detector, and setting the reaction program as follows: reacting at 42 ℃ for 30min; reacting at 94 ℃ for 5min; (94 ℃ reaction 15s.
(ii) Detection channel and reference fluorescence: the detection channel of the detector is FAM-TAMRA, and the reference fluorescence is set as none.
Example 2
A method for detecting BCR-ABL fusion gene by using the kit is the same as that of example 1, except that: the ratio of the BCR-ABL PCR reaction solution to the reference gene PCR reaction solution to the mixed enzyme solution (nuclease-free water) is 3:3:1, specifically, 9 muL and 3 muL of BCR-ABL PCR reaction solution, reference gene PCR reaction solution and mixed enzyme solution are respectively taken; the BCR-ABL PCR reaction solution consists of 3 muL of BCR-ABL1 p190 reaction solution, 3 muL of BCR-ABL1 p210 reaction solution and 3 muL of BCR-ABL1 p230 reaction solution.
Example 3
A method for detecting BCR-ABL fusion gene by using the kit is the same as that of example 1, except that: the ratio of the BCR-ABL PCR reaction solution, the reference gene PCR reaction solution and the mixed enzyme solution (nuclease-free water) is 3:4:1, specifically, taking 9 muL, 12 muL and 3 muL of BCR-ABL PCR reaction solution, reference gene PCR reaction solution and mixed enzyme solution respectively; the BCR-ABL PCR reaction solution consists of 3 muL of BCR-ABL1 p190 reaction solution, 3 muL of BCR-ABL1 p210 reaction solution and 3 muL of BCR-ABL1 p230 reaction solution.
Comparative example 1
A method for detecting BCR-ABL fusion gene by using a kit, which is the same as example 1, is different from the method in that the results of each component of BCR-ABL1 p190 reaction solution, BCR-ABL1 p210 reaction solution and BCR-ABL1 p230 reaction solution in tables 6 to 8 are shown in the following tables:
TABLE 8 BCR-ABL1 p190 reaction solution
TABLE 9 BCR-ABL1 p210 reaction solution
TABLE 10 BCR-ABL1 p230 reaction solution
Analysis of results
(1) And (3) effectiveness judgment: the CT value of the sample added with the reference substance liquid is not more than 36, and the fitting degree absolute value of the standard curve is not less than 0.980. The CT value of the sample added with the control solution should be more than or equal to 38 or show "Undet", and the following table 11 is referred to specifically.
TABLE 11
For reference gene PCR reaction solution C T Value of>36 and BCR-ABL190/210/230 reaction solution C T Value of>36, the sample is re-extracted by increasing the sampling amount, and then PCR detection is performed, and the result judgment is performed according to Table 11. If the reference gene PCR reaction solution C still appears T Value of>36 and BCR/ABL reaction solution C T Value of>36, the sample is determined to be unsatisfactory.
(2) Quantitative determination:
the BCR-ABL190/210/230 fusion gene in the specimen is positive, and the detection concentrations of the BCR-ABL190/210/230 and the reference gene are both more than or equal to 1 multiplied by 10 2 In copies, the following quantitative results analysis was performed.
The reference solution is set to 1 × 10 in BCR-ABL190/210/230 and internal reference reaction respectively 6 ，1×10 5 ，1×10 4 ，1×10 3 After the amplification is finished, the copies respectively obtain the detection concentration (A) of each sample BCR-ABL190/210/230 and the detection concentration (B) of the reference gene by using the two corresponding standard curves.
A. If the specimen is: BCR-ABL190/210/230RNA detection concentration>1×10 7 copies, should not be in the linear range, should be properly diluted and retested as appropriate. If the detection concentration of RNA in the reference gene PCR reaction solution sample>1×10 7 copies, should not be in the linear range, should be properly diluted and retested as appropriate.
B. If the specimen is: 1X 10 2 The detection concentration of BCR-ABL190/210/230RNA of copies is less than or equal to 1 x 10 7 copies, and 1X 10 2 The detection concentration of the internal reference RNA is less than or equal to 1 multiplied by 10 and is less than or equal to copies 7 copies, reported as the ratio of the detection concentration of BCR-ABL190/210/230 (i.e., A) to the detection concentration of the reference gene (B) (i.e., A/B). Times.100%.
When the kit is used for detecting the minimum residual focus, in order to detect fusion genes as low as one ten-thousandth, the internal reference gene C of a patient after treatment T The value must be less than 23.
For accurate quantification, reference gene C T When the value is less than 21, performing fusion gene detection on the RNA stock solution, diluting the stock solution by 100 times, and performing internal reference gene detection to ensure that the concentrations of corresponding detection genes are all in a linear range, wherein the report shows that the ratio of the detection concentration (A) of the fusion gene to the detection concentration (B) of the internal reference gene is (A/B). Times.1%.
The results are shown in Table 12 below.
From the results, the kit can be matched with a real-time fluorescent PCR technology to quantitatively detect p190/p210/p230 in RNA extracted from peripheral blood or bone marrow blood samples, has accurate detection result and high sensitivity (the minimum detection limit is 100 copies), and can provide important basis for diagnosis, curative effect monitoring, micro-residue detection and prognosis of malignant tumors.
Quality control product conformity rate: after the kits prepared in example 1 and comparative example 1 were stored at-20 ℃ for 50 days in the dark, 10 parts of the quality control materials were tested, respectively, and it was found that: the detection accuracy of the kit prepared in example 1 is 100%, and the detection accuracy of the kit prepared in comparative example 1 is 70%.
The above description is only illustrative of several embodiments of the present invention and should not be taken as limiting the scope of the invention. It should be noted that other persons skilled in the art can make modifications, substitutions, improvements and the like without departing from the spirit and scope of the present invention, and all of them belong to the protection scope of the present invention. Therefore, the scope of the invention is to be determined by the claims as set forth below.
Claims (10)
1. A kit for detecting BCR-ABL fusion genes is characterized by comprising BCR-ABL PCR reaction liquid, reference gene PCR reaction liquid, mixed enzyme liquid, reference substance liquid and reference substance liquid, wherein the mixing ratio of the BCR-ABL PCR reaction liquid to the reference gene PCR reaction liquid to the mixed enzyme liquid is 3 to 4:3 to 4:1.
2. the kit for detecting a BCR-ABL fusion gene according to claim 1, wherein the mixing ratio of the BCR-ABL PCR reaction solution, the reference gene PCR reaction solution and the mixed enzyme solution is 4:4:1.
3. the kit for detecting a BCR-ABL fusion gene according to claim 1, wherein the BCR-ABL PCR reaction solution comprises a BCR-ABL1 p190 reaction solution, a BCR-ABL1 p210 reaction solution and a BCR-ABL1 p230 reaction solution.
4. The kit for detecting a BCR-ABL fusion gene according to claim 3, wherein the BCR-ABL1 p190 reaction solution comprises the following components by volume ratio: 12.5. Mu.L of script II U + OneStp qRT-PCR Probe Kit, 1.25. Mu.L of script II U + Enzyme Mixt, 0.06. Mu.L of Triton 100, 0.04. Mu.L of isopropanol, 0.4. Mu.L of ROX internal reference, 0.6. Mu.L of BCR-ABL1 p190 upstream primer, 0.6. Mu.L of BCR-ABL1 p190 downstream primer, and 0.4. Mu.L of BCR-ABL1 Probe.
5. The kit for detecting a BCR-ABL fusion gene according to claim 3, wherein the BCR-ABL1 p210 reaction solution comprises the following components by volume ratio: 12.5. Mu.L of script II U + OneStep qRT-PCR Probe Kit, 1.25. Mu.L of script II U + Enzyme Mixt, 0.06. Mu.L of Triton 100, 0.04. Mu.L of isopropanol, 0.4. Mu.L of ROX internal reference, 0.6. Mu.L of BCR-ABL1 p210 upstream primer, 0.6. Mu.L of BCR-ABL1 p210 downstream primer, and 0.4. Mu.L of BCR-ABL1 Probe.
6. The kit for detecting a BCR-ABL fusion gene according to claim 3, wherein the BCR-ABL1 p230 reaction solution comprises the following components by volume ratio: 12.5 μ L of script II U + OneStep qRT-PCR Probe Kit, 1.25 μ L of script II U + Enzyme Mixt, 0.06 μ L of Triton 100, 0.04 μ L of isopropanol, 0.4 μ L of ROX internal reference, 0.6 μ L of BCR-ABL1 p230 upstream primer, 0.6 μ L of BCR-ABL1 p230 downstream primer, 0.4 μ L of BCR-ABL1 Probe.
7. The kit for detecting a BCR-ABL fusion gene according to claim 1, wherein said control solution comprises the following components by volume: 12.5. Mu.L of script II U + OneStep qRT-PCR Probe Kit, 1.25. Mu.L of script II U + Enzyme Mixt, 0.4. Mu.L of ROX internal reference, 0.6. Mu.L of ABL1 upstream primer, 0.6. Mu.L of ABL1 downstream primer, and 0.4. Mu.L of ABL1 Probe.
8. The kit for detecting a BCR-ABL fusion gene according to claim 1, wherein said reference solution comprises the following components by volume: 12.5. Mu.L of script II U + OneStep qRT-PCR Probe Kit, 1.25. Mu.L of script II U + Enzyme Mixt, 0.4. Mu.L of ROX internal reference, 0.6. Mu.L of BCR-ABL1 p210 upstream primer, 0.6. Mu.L of ABL1 downstream primer, and 0.4. Mu.L of ABL1 Probe.
9. The kit for detecting a BCR-ABL fusion gene according to any one of claims 1 to 8, wherein said mixed enzyme solution comprises nuclease-free water.
10. The use of the kit for detecting a BCR-ABL fusion gene according to any one of claims 1 to 9 in the biological and medical fields.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210873620.0A CN115851924A (en) | 2022-07-24 | 2022-07-24 | Kit for detecting BCR-ABL fusion gene and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210873620.0A CN115851924A (en) | 2022-07-24 | 2022-07-24 | Kit for detecting BCR-ABL fusion gene and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115851924A true CN115851924A (en) | 2023-03-28 |
Family
ID=85660368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210873620.0A Pending CN115851924A (en) | 2022-07-24 | 2022-07-24 | Kit for detecting BCR-ABL fusion gene and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115851924A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1995386A (en) * | 2006-08-22 | 2007-07-11 | 上海复星医药（集团）股份有限公司 | BCR-ABL gene fluorescence quantitative RT-PCR primer and probe and reagent kit |
| CN102827937A (en) * | 2012-09-06 | 2012-12-19 | 上海源奇生物医药科技有限公司 | Primer and probe for detecting relative fusion genes of leukemia and kit of primer and probe |
| CN110358825A (en) * | 2018-04-09 | 2019-10-22 | 苏州云泰生物医药科技有限公司 | Detect the kit and its application method of people BCR-ABL fusion |
-
2022
- 2022-07-24 CN CN202210873620.0A patent/CN115851924A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1995386A (en) * | 2006-08-22 | 2007-07-11 | 上海复星医药（集团）股份有限公司 | BCR-ABL gene fluorescence quantitative RT-PCR primer and probe and reagent kit |
| CN102827937A (en) * | 2012-09-06 | 2012-12-19 | 上海源奇生物医药科技有限公司 | Primer and probe for detecting relative fusion genes of leukemia and kit of primer and probe |
| CN110358825A (en) * | 2018-04-09 | 2019-10-22 | 苏州云泰生物医药科技有限公司 | Detect the kit and its application method of people BCR-ABL fusion |
Non-Patent Citations (1)
| Title |
|---|
| 曾庆仁等: "《免疫学和病原检测技术及基础与创新实验 供临床医学基础医学护理学药学等专业使用》", 华中科技大学出版社, pages: 197 - 198 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230035871A1 (en) | Method, composition and kit for fluorescent quantitative pcr, and use thereof | |
| CN107460242B (en) | Detection kit capable of simultaneously detecting multiple high-drug-resistance genes and application thereof | |
| CN110724741B (en) | Primer, probe and kit for detecting minimal residual leukemia related fusion gene | |
| CN112852984B (en) | Detection system for urinary system infection pathogen, kit and application thereof | |
| CN102912028A (en) | Amplification composite for detecting microdeletion of Y-chromosome and detection kit | |
| CN112226538A (en) | Primer-probe combination, kit and method for detecting novel coronavirus | |
| CN112501301A (en) | Primer and probe combination for quantitatively detecting BCR-ABL fusion gene, kit and using method thereof | |
| CN113718021A (en) | Primer, probe and kit for quantitatively detecting BCR-ABL1 fusion gene | |
| CN104673891A (en) | Detection method and kit for spinal muscular atrophy related gene mutation | |
| Sangkitporn et al. | Multicenter validation of fully automated capillary electrophoresis method for diagnosis of thalassemias and hemoglobinopathies in Thailand | |
| CN110484625A (en) | For detecting primer combination of probe object, kit and the detection method of PRKY gene methylation | |
| CN110551816A (en) | kit for detecting human PML-RARa fusion gene and use method thereof | |
| CN115851924A (en) | Kit for detecting BCR-ABL fusion gene and application thereof | |
| CN110656171B (en) | Use of small nucleolus ribonucleic acid SNORD33 as biomarker for preparing detection kit | |
| CN108660213B (en) | Application of reagent for detecting three non-coding RNAs and kit | |
| CN112986164B (en) | Anti-heparin stable alpha-L-fucosidase detection kit and application thereof | |
| CN111560429B (en) | Application of circRNA marker for diagnosing thalassemia | |
| CN116516003A (en) | Detection system and detection method for typing and quantitatively detecting BCR-ABL P210 fusion gene based on digital PCR platform | |
| CN111455094B (en) | Composition, kit, application and method for detecting deep infection fungi | |
| CN111621557B (en) | Kit for detecting osteoporosis susceptibility gene by cocktail and using method thereof | |
| CN110358825A (en) | Detect the kit and its application method of people BCR-ABL fusion | |
| CN111850129B (en) | Primer pair, kit and method for detecting stability of NR21 locus of microsatellite | |
| CN110804663A (en) | Primer, kit and detection method for detecting human CYP2C19 gene mutation | |
| CN108048529B (en) | Quality control product of lung cancer methylation gene detection kit capable of being stably stored and application | |
| CN111206105A (en) | Molecular identification method of fresh and dry Bungarus Parvus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |